Literature DB >> 15308126

Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB.

Yi Zheng1, Sergey Ryazantsev, Kazuhiro Ohmi, Hui-Zhi Zhao, Nora Rozengurt, Donald B Kohn, Elizabeth F Neufeld.   

Abstract

Mucopolysaccharidosis IIIB (MPS IIIB) is a lysosomal storage disorder caused by mutations in NAGLU, the gene encoding alpha-N-acetylglucosaminidase. The disease is characterized by profound mental retardation and eventual neurodegeneration, but relatively mild somatic manifestations. There is no available therapy. We have used a mouse knockout model of the disease to test therapy by genetically modified bone marrow. Bone marrow from Naglu -/- male mice was transduced with human NAGLU cDNA in an MND-MFG vector, and transplanted into 6- to 8-week-old lethally irradiated female -/- mice. Sham-treated mice received bone marrow transduced with eGFP cDNA in an MND vector. alpha-N-Acetylglucosaminidase activity in plasma and leukocytes, measured 3 and 6 months after transplantation, varied from marginal to nearly 30 times wild-type. A low level of alpha-N-acetylglucosaminidase activity, as little as provided by transplantation of unmodified Naglu +/+ bone marrow, could normalize biochemical defects (glycosaminoglycan storage and beta-hexosaminidase elevation) in liver and spleen, but a very high level was required for an effect on kidney. Effects on the brain were best seen by examination of cellular morphology using light and electron microcopy. Mice that expressed very high levels of alpha-N-acetylglucosaminidase in blood had an increased number of normal-appearing neurons in the cortex and other parts of the brain, while microglia with engorged lysosomes had almost completely disappeared. Immunohistochemistry showed a marked decrease of staining for subunit c of mitochondrial ATP synthase and for Lamp1, markers of neuronal and microglial pathology, respectively, as well as a decrease in staining for glial fibrillary acid protein, a marker of activated astrocytes. These results show that genetically modified cells of hematopoietic origin can reduce the pathologic manifestations of MPS IIIB in the Naglu -/- mouse brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308126     DOI: 10.1016/j.ymgme.2004.06.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  24 in total

1.  Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Authors:  Coy D Heldermon; Kevin K Ohlemiller; Erik D Herzog; Carole Vogler; Elizabeth Qin; David F Wozniak; Yun Tan; John L Orrock; Mark S Sands
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).

Authors:  Jakub Tolar; In-Hyun Park; Lily Xia; Chris J Lees; Brandon Peacock; Beau Webber; Ron T McElmurry; Cindy R Eide; Paul J Orchard; Michael Kyba; Mark J Osborn; Troy C Lund; John E Wagner; George Q Daley; Bruce R Blazar
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

Review 3.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

4.  Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening.

Authors:  Jessica Y Rathbun; Magali E Droniou; Robert Damoiseaux; Kevin G Haworth; Jill E Henley; Colin M Exline; Hyeryun Choe; Paula M Cannon
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

5.  Neonatal Bone Marrow Transplantation in MPS IIIA Mice.

Authors:  Adeline A Lau; N Jannah Shamsani; Leanne K Winner; Sofia Hassiotis; Barbara M King; John J Hopwood; Kim M Hemsley
Journal:  JIMD Rep       Date:  2012-08-10

6.  Gene therapy for cardiovascular manifestations of lysosomal storage diseases.

Authors:  Meg M Sleeper; Mark E Haskins; Katherine P Ponder
Journal:  Heart Metab       Date:  2008

7.  Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B.

Authors:  Sergey Ryazantsev; Wei-Hong Yu; Hui-Zhi Zhao; Elizabeth F Neufeld; Kazuhiro Ohmi
Journal:  Mol Genet Metab       Date:  2006-12-20       Impact factor: 4.797

8.  Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.

Authors:  Alexander Langford-Smith; Fiona L Wilkinson; Kia J Langford-Smith; Rebecca J Holley; Ana Sergijenko; Steven J Howe; William R Bennett; Simon A Jones; Je Wraith; Catherine Lr Merry; Robert F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

9.  Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Authors:  Tehila Mayer-Sonnenfeld; Dana Avrahami; Yael Friedman-Levi; Ruth Gabizon
Journal:  Cell Mol Neurobiol       Date:  2008-03-19       Impact factor: 5.046

10.  Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts.

Authors:  Shih-hsin Kan; Larisa A Troitskaya; Carolyn S Sinow; Karyn Haitz; Amanda K Todd; Ariana Di Stefano; Steven Q Le; Patricia I Dickson; Brigette L Tippin
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.